Product Images Aripiprazole

This text seems to be a mix of alphanumeric codes, a drug name, and some other unidentified information, making it not-available for generating a useful description.*

This appears to be the label of a medication called "Aripiprazole", packaged as USP 30 tablets. The label includes dosage information but no other relevant details.*

This is a description providing details of a drug called Aripiprazole. The drug comes in the form of tablets with a strength of 2mg. The tablets package size is 50 and the lot number is OOOO0OON. The package has been assigned the NDC code 63739.069-33. The usual dosage amount and administration is not available.*

This is a description for a medication named Aripiprazole, which comes in tablet form and is made in India. The label includes a product code and a pharmacist's note indicating dosage instructions.*

This is a table showing the effect of different drugs on the metabolism of aripiprazole, a medication used to treat certain mental illnesses. The drugs listed are either inhibitors or inducers of certain enzymes in the body that affect how aripiprazole is broken down. The table also shows the fold change in Aripiprazole and a confidence interval. Further context is not available from the given text.*

This text provides information on the effect of different drugs on Aripiprazole, a medication used for schizophrenia, bipolar disorder, and depression. The text lists the drugs that inhibit or induce the activity of specific enzymes responsible for metabolizing Aripiprazole, such as CYP3A4 and CYP2D6. It also mentions the impact of gastric acid blockers and other drugs, such as valproate and lithium, on Aripiprazole. The text includes a chart indicating the fold change and 90% confidence interval of Dehydro-Aripiprazole concerning a reference value without the presence of the interacting drug.*

This is a description of a study on the effects of avripiprazole on special populations. The populations studied include individuals with poor versus extensive metaboizer AUC, females versus males, and individuals aged 18-64 versus those over 65 years old. They also studied individuals with varying degrees of hepatic impairment and renal impairment. The study measured the fold change and percent change relative to a reference group. There is no clear information provided on the results of the study.*

This text seems to be describing a study of the effect of various factors on the pharmacokinetics of a drug, likely Aripiprazole. The study investigated how factors such as CYP2D6 metabolism, gender, age, and hepatic/renal impairment affect the AUC (area under the curve) and maximum concentration of the drug in the body. The table provided shows fold change and CI (confidence interval) data for the dehydro-Aripiprazole metabolite. However, without additional information or context, it is not clear what the results of the study were or what the implications are for medical treatment.*

This appears to be a table showing the proportion of subjects with a relapse and the number of subjects at risk for a drug called Ariplprazole versus a placebo. The table includes data for various time points after randomization.*

This data appears to be a table showing the proportion of subjects with relapse over time for a trial comparing aripiprazole and placebo. The numbers on the left column represent the proportion with relapse, while the numbers along the top represent the number of days from randomization. The table also includes the number of subjects at risk for each time point.*

This is a clinical trial report for Ariplprazole, a medication that is being tested to determine its effectiveness in preventing relapse in subjects. The report includes a chart displaying the proportion of subjects experiencing relapse over time on Aripiprazole compared to a placebo, as well as the number of subjects at risk for each treatment at different points in time following randomization. The chart spans 28 to 364 days after randomization.*